USA 116 , 1961919625 (2019)
Xenobiotica 28 :1083-1092 (1998)
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Your body receives the injection via a vein
Key Features NNMT-Targeted Molecule Used to support studies involving nicotinamide N-methyltransferase pathways Metabolic Mechanism Insight Suitable for analysing enzyme-linked metabolic processes Cellular Stress Models Selected for research involving oxidative or metabolic challenge High Research Purity Supplied as a lyophilised solid suitable for controlled laboratory use Research Only Intended for qualified professionals conducting scientific investigation Research Context In controlled laboratory settings, 5-Amino-1MQ 10mg is used to explore: Enzyme-regulated biochemical pathways Cellular responses to altered NNMT activity Mechanisms associated with oxidative balance Metabolic stress models Gene-regulated signalling changes in vitro Its compact molecular structure enables efficient cell penetration, making it suitable for research requiring intracellular access and precise enzymatic targeting
The predominant PDHA1 derived mRNA (isoform 1) encodes a precursor protein of 390 amino acids
